Industry: Biopharma / Rare Disease
Engagement Type: Corporate Narrative & Digital Repositioning
Background
A leader in rare disease treatment needed to balance its investor-focused content with a more patient- and clinician-centric narrative to better engage stakeholders across the healthcare ecosystem.
Problem
Corporate messaging emphasized financial updates, overshadowing stories of patient impact and scientific leadership. Social engagement was limited, particularly among advocacy and clinical communities.
Solution
Ringer Sciences conducted a digital audit covering web, social, and media presence. The analysis informed a repositioning strategy that included new messaging pillars, earned media targeting, SEO optimization, and stakeholder-specific content recommendations.
Results
- Increased narrative balance, shifting from over 70% investor-focused content to a near 50/50 mix including clinical, access, and patient-centered themes.
- Drove a 15-20% increase in average engagement rates on patient- and HCP-facing content, signaling improved relevance across target audiences.
- Improved time-on-page and reduced bounce rates by 10-15% on high-priority messaging pages, reflecting stronger alignment with user expectations.
- Boosted organic search visibility through SEO-aligned copy and keyword repositioning, with branded click-through rates improving by 20-25% over the 3-month post-launch period.
Outcome
Realigned the corporate narrative to more effectively engage patients, healthcare professionals, and advocates, strengthening brand trust and visibility across digital channels.
